Literature DB >> 11158797

Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: A double-masked, randomized, one-year study.

J H Lass1, G L Eriksson, L Osterling, C V Simpson.   

Abstract

OBJECTIVE: To compare the long-term effects on corneal endothelial cell density and corneal thickness of latanoprost and the fixed combination latanoprost-timolol to timolol.
DESIGN: Double-masked, randomized, prospective, multicenter clinical trial. PARTICIPANTS: Three hundred sixty-nine subjects with bilateral ocular hypertension or open-angle glaucoma who had a baseline central corneal endothelial cell density of at least 1500 cells/mm(2), central corneal thickness of less than 0.68 mm, no corneal pathologic condition on slit-lamp examination, and intraocular pressure of less than 22 mmHg after a 3-week run-in on timolol, 0.5%, once daily were included. INTERVENTION: Subjects were randomly assigned to treatment with latanoprost 0.005% (n = 127), fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116), or timolol 0.5% (n = 126) one drop, once daily in the morning for 1 year. All subjects were treated in both eyes. Specular microscopy and ultrasonic pachymetry were performed before treatment, and after 6 and 12 months of treatment. MAIN OUTCOME MEASURES: Mean percent change in central endothelial cell density and central corneal thickness after 1 year of treatment.
RESULTS: For both corneal endothelial cell density and corneal thickness, the mean percent changes from baseline were similar in all three treatment groups. Mean percent endothelial cell change at 1 year from baseline for latanoprost, FC, and timolol was 0.3 +/- 2.2%, 0.1 +/- 1.8%, 0.0 +/- 2.5% (mean +/- standard deviation; 95% confidence interval: latanoprost vs timolol -0.2-1.0; FC vs timolol -0.4-0.7) and mean percent change in corneal thickness was -1.1 +/- 2.5%, -1.0 +/- 2.0%, 0.2 +/- 3.1%, respectively.
CONCLUSIONS: Latanoprost and FC are equivalent to timolol regarding long-term corneal effects after 1 year of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158797     DOI: 10.1016/s0161-6420(00)00531-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  Circadian variations in central corneal thickness and intraocular pressure in patients with glaucoma.

Authors:  P Fogagnolo; L Rossetti; F Mazzolani; N Orzalesi
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.

Authors:  Ai-Wei Liu; Lin-Yang Gan; Xiang Yao; Jian Zhou
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

3.  Comparison of central corneal thickness measurements obtained by community optometrists to those obtained in secondary care.

Authors:  Laura Hughes; Cheng Yi Loo; Brian Hogan; Huai Ling Tan; Ling Shan Tang; Andrew J Tatham
Journal:  Eye (Lond)       Date:  2018-07-23       Impact factor: 3.775

4.  Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma.

Authors:  Akira Sawada; Tetsuya Yamamoto; Naoyoshi Takatsuka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-21       Impact factor: 3.117

Review 5.  Corneal Endothelial Cell Loss in Glaucoma and Glaucoma Surgery and the Utility of Management with Descemet Membrane Endothelial Keratoplasty (DMEK).

Authors:  Neeru A Vallabh; Stephnie Kennedy; Riccardo Vinciguerra; Keri McLean; Hannah Levis; Davide Borroni; Vito Romano; Colin E Willoughby
Journal:  J Ophthalmol       Date:  2022-01-30       Impact factor: 1.974

6.  [Measurement of corneal thickness in glaucoma patients].

Authors:  H Dave; A Kutschan; A Pauer; W Wiegand
Journal:  Ophthalmologe       Date:  2004-09       Impact factor: 1.059

Review 7.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy.

Authors:  Joel M Fain; Sameer Kotak; Jack Mardekian; Jason Bacharach; Deepak P Edward; Steven Rauchman; Teresa Brevetti; Janet L Fox; Cherie Lovelace
Journal:  BMC Ophthalmol       Date:  2011-06-13       Impact factor: 2.209

9.  Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.

Authors:  Gail F Schwartz; Sameer Kotak; Jack Mardekian; Joel M Fain
Journal:  BMC Ophthalmol       Date:  2011-06-14       Impact factor: 2.209

10.  A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop.

Authors:  Yukihisa Takada; Yuka Okada; Norihito Fujita; Shizuya Saika
Journal:  Case Rep Ophthalmol Med       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.